A single institution experience on 314 newly diagnosed advanced Hodgkin lymphoma patients: the role of ABVD in daily practice.

Eur J Haematol 2014 Nov 26;93(5):392-9. Epub 2014 May 26.

Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia.

Based on the results of clinical trials, there is no global consensus on the optimal first-line therapy for patients with advanced Hodgkin lymphoma (HL) with both ABVD and BEACOPP currently being used. However, the results of clinical trials are usually better than those in daily practice. We thus describe here our experience on 314 advanced classical HL patients treated with ABVD at the Clinical Center of Serbia and associated centers between 1997 and 2008. The median follow-up for all patients was 91 months; the estimated 5-yr event-free survival was 62% and the 5-yr overall survival (OS) 76%. Multivariate Cox regression analysis revealed that patients with IPS ≥ 3 and extranodal disease involving more than one site have a poorer outcome. The data presented here show on overall improvement in outcome as compared to more previous data and illustrate the problems of treating advanced stage HL outside the setting of a clinical trial.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12364DOI Listing
November 2014
83 Reads
2 Citations
2.070 Impact Factor

Publication Analysis

Top Keywords

experience 314
8
daily practice
8
clinical trials
8
advanced hodgkin
8
hodgkin lymphoma
8
patients
5
5-yr event-free
4
estimated 5-yr
4
event-free survival
4
62% 5-yr
4
multivariate cox
4
cox regression
4
76% multivariate
4
survival 76%
4
91 months estimated
4
5-yr survival
4
survival 62%
4
follow-up patients
4
abvd clinical
4
clinical center
4

References

(Supplied by CrossRef)
Are macrophages the bad guys in Hodgkin lymphoma?
Diehl et al.
Nature 2010
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Eichenauer et al.
Ann Oncol 2011

Similar Publications